These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 8709244)

  • 1. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles.
    Turpin JA; Terpening SJ; Schaeffer CA; Yu G; Glover CJ; Felsted RL; Sausville EA; Rice WG
    J Virol; 1996 Sep; 70(9):6180-9. PubMed ID: 8709244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in vitro ejection of zinc from human immunodeficiency virus (HIV) type 1 nucleocapsid protein by disulfide benzamides with cellular anti-HIV activity.
    Tummino PJ; Scholten JD; Harvey PJ; Holler TP; Maloney L; Gogliotti R; Domagala J; Hupe D
    Proc Natl Acad Sci U S A; 1996 Feb; 93(3):969-73. PubMed ID: 8577770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of murine leukemia virus by compounds that react with the zinc finger in the viral nucleocapsid protein.
    Rein A; Ott DE; Mirro J; Arthur LO; Rice W; Henderson LE
    J Virol; 1996 Aug; 70(8):4966-72. PubMed ID: 8764002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of zinc is required for processing of the mature nucleocapsid protein of human immunodeficiency virus, type 1, by the viral protease.
    Wondrak EM; Sakaguchi K; Rice WG; Kun E; Kimmel AR; Louis JM
    J Biol Chem; 1994 Sep; 269(35):21948-50. PubMed ID: 8071314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds.
    Rice WG; Schaeffer CA; Harten B; Villinger F; South TL; Summers MF; Henderson LE; Bess JW; Arthur LO; McDougal JS
    Nature; 1993 Feb; 361(6411):473-5. PubMed ID: 8429889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS.
    Rice WG; Supko JG; Malspeis L; Buckheit RW; Clanton D; Bu M; Graham L; Schaeffer CA; Turpin JA; Domagala J; Gogliotti R; Bader JP; Halliday SM; Coren L; Sowder RC; Arthur LO; Henderson LE
    Science; 1995 Nov; 270(5239):1194-7. PubMed ID: 7502043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins.
    Rice WG; Baker DC; Schaeffer CA; Graham L; Bu M; Terpening S; Clanton D; Schultz R; Bader JP; Buckheit RW; Field L; Singh PK; Turpin JA
    Antimicrob Agents Chemother; 1997 Feb; 41(2):419-26. PubMed ID: 9021201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral RNA annealing activities of human immunodeficiency virus type 1 nucleocapsid protein require only peptide domains outside the zinc fingers.
    De Rocquigny H; Gabus C; Vincent A; Fournié-Zaluski MC; Roques B; Darlix JL
    Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6472-6. PubMed ID: 1631144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing.
    Bardy M; Gay B; Pébernard S; Chazal N; Courcoul M; Vigne R; Decroly E; Boulanger P
    J Gen Virol; 2001 Nov; 82(Pt 11):2719-2733. PubMed ID: 11602784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of nucleocapsid of HIV-1 in virus assembly.
    Dawson L; Yu XF
    Virology; 1998 Nov; 251(1):141-57. PubMed ID: 9813210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins.
    Huang M; Maynard A; Turpin JA; Graham L; Janini GM; Covell DG; Rice WG
    J Med Chem; 1998 Apr; 41(9):1371-81. PubMed ID: 9554870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811.
    Dorfman T; Göttlinger HG
    J Virol; 1996 Sep; 70(9):5751-7. PubMed ID: 8709190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.
    Huang M; Orenstein JM; Martin MA; Freed EO
    J Virol; 1995 Nov; 69(11):6810-8. PubMed ID: 7474093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions.
    Davis DA; Yusa K; Gillim LA; Newcomb FM; Mitsuya H; Yarchoan R
    J Virol; 1999 Feb; 73(2):1156-64. PubMed ID: 9882317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag-Pol precursor protein.
    Liu H; Wu X; Xiao H; Conway JA; Kappes JC
    J Virol; 1997 Oct; 71(10):7704-10. PubMed ID: 9311854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers.
    Turpin JA; Song Y; Inman JK; Huang M; Wallqvist A; Maynard A; Covell DG; Rice WG; Appella E
    J Med Chem; 1999 Jan; 42(1):67-86. PubMed ID: 9888834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors.
    Rice WG; Turpin JA; Schaeffer CA; Graham L; Clanton D; Buckheit RW; Zaharevitz D; Summers MF; Wallqvist A; Covell DG
    J Med Chem; 1996 Sep; 39(19):3606-16. PubMed ID: 8809151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency.
    Kaplan AH; Manchester M; Swanstrom R
    J Virol; 1994 Oct; 68(10):6782-6. PubMed ID: 8084015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein zinc ejection activity of disulfide benzamides and benzisothiazolones: correlation with anti-HIV and virucidal activities.
    Tummino PJ; Harvey PJ; McQuade T; Domagala J; Gogliotti R; Sanchez J; Song Y; Hupe D
    Antimicrob Agents Chemother; 1997 Feb; 41(2):394-400. PubMed ID: 9021197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.